โ ViewAdvancedBusiness & Law โบ Corporate Finance & Governance
Pharmaceutical Lobbying Group PhRMA Appoints Former House Leader Eric Cantor as CEO
The Pharmaceutical Research and Manufacturers of America (PhRMA) has named former House Majority Leader Eric Cantor as its new president and CEO. Cantor, who transitions from a senior role at Moelis & Company, will take the helm of the powerful trade group this November to navigate an increasingly complex regulatory and political landscape.
2mยท๐ 0
โ ViewAdvancedIndustry Deep Dives โบ Healthcare & Pharma
Sanofi Forms Strategic Partnership With Cheplapharm For Mature Medicines
Sanofi has announced a new strategic partnership with Cheplapharm, transferring a portfolio of 20 mature medicines and three manufacturing sites to the company. As part of the deal, Sanofi will receive a 26.4% equity stake in Cheplapharm, signaling a shift in focus toward newer, high-growth pharmaceutical assets.
2mยท๐ 0
โ ViewAdvancedIndustry Deep Dives โบ Healthcare & Pharma
Eli Lilly Expands Pipeline with $2.88 Billion Acquisition
Eli Lilly is leveraging the massive profits from its obesity drug portfolio to acquire Merida Biosciences. This move signals a strategic shift to diversify the company's offerings beyond weight-loss treatments.
1mยท๐ 0
โ ExplanationAdvancedIndustry Deep Dives โบ Healthcare & Pharma
Teva Pharmaceutical โ Israel's Global Generic Drug Maker
A financial and strategic breakdown of Teva Pharmaceutical, analyzing its Pivot to Growth momentum, generic drug leadership, innovative pipeline, and debt optimization.
2mยท๐ 0
โ ExplanationAdvancedIndustry Deep Dives โบ Healthcare & Pharma
Novo Nordisk โ Denmark's Diabetes and Obesity Treatment Leader
An analysis of Novo Nordisk A/S, focusing on its dominant position in GLP-1 diabetes and obesity treatments, financial growth metrics, manufacturing expansion, and market outlook.
4mยท๐ 0
โ ExplanationAdvancedIndustry Deep Dives โบ Healthcare & Pharma
Novartis โ Switzerland's Pharmaceutical Giant
An in-depth review of Novartis AG, analyzing its transformation into a pure-play innovative medicines enterprise, financial results, core therapeutic platforms, and strategic outlook.
4mยท๐ 0
โ ExplanationAdvancedIndustry Deep Dives โบ Healthcare & Pharma
AstraZeneca โ UK's Pharmaceutical Powerhouse
A profile of AstraZeneca plc, detailing its leadership in oncology and biopharmaceuticals, financial results, R&D pipeline, and competitive position in global healthcare.
4mยท๐ 0
โ ViewUnderstandingCountry Profiles โบ Country Profiles
Belgium: Economic Future โ Pharma, Logistics, and the EU Institutional Economy
This article provides a comprehensive view of Belgium's economic outlook, focusing on key growth engines like the life sciences sector and the Port of Antwerp-Bruges logistics hub. It also explores the unique service-oriented economy driven by the presence of European Union institutions. Finally, the analysis addresses the persistent regional divergence and its implications for long-term competitiveness.
9.7mยท๐ 0
โ ExplanationAdvancedCountry Profiles โบ Country Profiles
Switzerland: Economic Future โ Pharma Giant, Crypto Valley, and the End of Banking Secrecy
An in-depth exploration of Switzerland's modern economic landscape, detailing how the nation has diversified beyond banking secrecy into high-margin pharmaceutical manufacturing, a pioneering digital asset and blockchain ecosystem in Zug, and physical commodity trading networks.
9mยท๐ 1
โ Explanation๐ StandardAdvancedHealthcare Economics โบ Pharmaceutical Economics
The Global Healthcare Business โ Who Profits From Sickness
Healthcare is a $10 trillion global industry. Here's who the major players are โ from device makers to hospital chains to pharmaceutical distributors โ and how the money flows.
3mยท๐ 2